Merck KGaA, Darmstadt, Germany and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab Merck KGaA, Darmstadt, Germany and Pfizer announced the opening of trial sites for an international Phase III study of avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer. [Pfizer Inc.] Press Release Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase I/II Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hodgkin Lymphoma Seattle Genetics, Inc. and Bristol-Myers Squibb announced that the companies have initiated a Phase I/II clinical trial of ADCETRIS in combination with Opdivo for patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and cutaneous T-cell lymphoma. [Seattle Genetics, Inc.] Press Release Alnylam Initiates Dosing in PNH Patients in Phase I/II Clinical Trial for ALN-CC5 Alnylam Pharmaceuticals, Inc. announced that it initiated the final phase of its Phase I/II clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. [Alnylam Pharmaceuticals, Inc.] Press Release Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies Cellectis announced the submission of a clinical trial application to the Medicines & Healthcare products Regulatory Agency requesting approval to initiate UCART19 First-in-Human clinical investigation in leukemia in the United Kingdom. [Cellectis] Press Release Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Sarepta Therapeutics, Inc. announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review Sarepta’s new drug application for eteplirsen, on January 22, 2016 [Sarepta Therapeutics] Press Release Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 (PH1) in Healthy Volunteers Dicerna Pharmaceuticals, Inc. announced it has initiated dosing in the first clinical trial of DCR-PH1, its investigational therapy for the treatment of PH1. [Dicerna Pharmaceuticals, Inc.] Press Release Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6 Regen BioPharma, Inc., announced identification of a series of compounds that have been identified by biochemical testing which interact with the company’s newly identified immune checkpoint NR2F6. [Regen BioPharma, Inc. (PR Newswire Association LLC)] Press Release Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate Regen BioPharma, Inc., announced receipt of a communication from the U.S. Food and Drug Administration, allowing for initiation of clinical trials under its investigational new drug (IND) #15376. The clearance of the IND allows the company to initiate clinical trials of HemaXellerate, a personalized immune-modulatory cell therapy that has demonstrated benefit in animal models of aplastic anemia. [Regen BioPharma, Inc. (PR Newswire Association LLC)] Press Release VistaGen Secures Exclusive Worldwide Commercial Rights to Three Proprietary Stem Cell Technologies from University Health Network VistaGen Therapeutics, Inc. announced that it has secured exclusive worldwide commercial rights to three patent-pending stem cell technologies from University Health Network. [VistaGen Therapeutics, Inc.] Press Release |